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This study assessed the efficacy of anorganic bonemineral coated with P-15 peptide (ABM/P-15) on tibia defect repair longitudinally
in both normal and osteoporotic rats in vivo. A paired design was used. 24 Norwegian brown rats were divided into normal and
osteoporotic groups. 48 cylindrical defects were created in proximal tibias bilaterally. Defects were filled with ABM/P-15 or left
empty.Osteoporotic statuswas assessed bymicroarchitectural analysis.Microarchitectural properties of proximal tibial defectswere
evaluated at 4 time points. 21 days after surgery, tibias were harvested for histology and histomorphometry. Significantly increased
bone volume fraction, surface density, and connectivity were seen in all groups at days 14 and 21 compared with day 0. Moreover,
the structure type of ABM/P-15 group was changed toward typical plate-like structure. Microarchitectural properties of ABM/P-
15 treated newly formed bones at 21 days were similar in normal and osteoporotic rats. Histologically, significant bone formation
was seen in all groups. Interestingly, significantly increased bone formation was seen in osteoporotic rats treated with ABM/P-15
indicating optimized healing potential. Empty defects showed lower healing potential in osteoporotic bone. In conclusion, ABM/P-
15 accelerated bone regeneration in osteoporotic rats but did not enhance bone regeneration in normal rats.
1. Introduction
Oneof themajor clinical challenges, in orthopedic and recon-
structive surgeries, is filling large osseous defects [1, 2]. Bone
defects can be due to trauma, surgical procedures, tumor
resection, or age-related skeletal diseases such as osteoporosis
[3]. Osteoporosis (OP) is a skeletal disorder affecting bone
tissue and is characterized by loss of bone mass to a critical
level, for bone fractures. Osteoporosis is a public health
care problem because of the increase in elderly population,
especially elderly women, who suffer additional bone loss due
to menopause [3, 4]. In this study an osteoporotic rat model
was used to mimic reduced bone quality as found in elderly
patients, who are characterized by bone loss related increased
fracture risk and decreased fracture healing potential [5].
Large bone defects require bone grafting in order to get
healing [6, 7]. Autograft has been the preferred graft material
and considered as gold standard. However, there are several
difficulties connected to the use of autograft material, for
example, getting adequate amount of material and morbidity
at donor site [7–10]. Furthermore the current allograft and
xenograft products might cause graft versus host reaction,
because the histocompatibility antigens from the graft are
different from those of the host [9].
Because of the problems associated with autograft, allo-
graft, or xenograft, bioactive graft materials are getting
increasing attention. These bone substitutes have attracted
great interest because of their potential to be a substitute
for autogenous bone, with no supply limits and low risk of
adverse effects [7].
The combination of anorganic bone mineral (ABM/P-
15) and synthetic peptide P-15 acts as a bioactive attach-
ment factor that aims to replicate type I collagen binding
mechanism with osteogenic precursor cells in bone tissue
[11, 12]. The ABM/P-15 has been tested in several animal
studies, presentingABM/P-15with properties similar to those
of autogenous bone [10, 13].The effectiveness of ABM/P-15 in
clinical dental use has been shown in a few studies [14, 15].The
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efficacy of ABM/P-15 in orthopedics has been addressed in a
number of animal studies [16, 17] but only one clinical study
has been done in human [18]. However, there is no published
literature on the effects of ABM/P-15 on bone defect repair in
vivo in particular osteoporotic model longitudinally.
It was hypothesized that ABM/P-15 would accelerate
bone regeneration in both normal and osteoporotic bones.
Thus the purpose of this study was to assess the efficacy of
ABM/P-15 on bone healing in normal rat and osteoporotic rat
defects, evaluated as histomorphometry on bone formation
and changes in microarchitecture.
2. Materials and Methods
2.1. ABM/P-15. Anorganic bone mineral is a microporous
bovine-derived hydroxyapatite. The P-15 peptide is synthetic
replica of the (766)GTPGPQGIAGQRGVV(780) sequence
in the 𝛼(I)chain of type I collagen. The P-15 sequence
has been shown to induce bone healing, similar to type
I collagen [13]. When bound to anorganic bone mineral,
P-15 peptide serves as a surrogate for collagen [19]. P-15
interacts with osteogenic precursor cells, which contains
𝛼2𝛽1-integrins.The binding of 𝛼2𝛽1-integrins to P-15 initiates
natural intra- and extracellular signaling pathways, inducing
the production of growth factors, bonemorphogenic proteins
[20], and cytokines. Ultimately, the injection of ABM/P-15
into a bony defect site might initiate new bone formation and
optimize the natural bone healing process [13]. ABM/P-15 (i-
Factor Putty, Cerapedics Inc., Westminster, USA) substitute
was donated by Ortotech (Kolding, Denmark), delivered in
form of putty in 5.0 cc syringes.
2.2. Animals. Twenty-four female brown Norwegian inbred
rats (BN/SsNOlaHsd), 4 months of age, with a mean body
weight of 194.5 ± 10.1 grams, were purchased from Harlan
Laboratories GmbH (Venray, Netherlands) and used in this
study. These rats were housed in the Biomedical Laboratory
Facility, University of Southern Denmark and were accli-
mated for two weeks prior to the experimental initiation.The
environment was temperature-controlled (21∘C ± 2∘C/40–
60% humidity). The normal rats received standard food,
and the ovariectomized rats were given a phytoestrogen-
free calcium deficient diet containing <0.15% calcium and
<0.1% phosphorus (Brogaarden, Lynge, Denmark) starting
two months before tibial defects were created. Body weight
was recorded over time, and physical activities were observed
daily. Housing conditions and applied experimental protocol
were in accordance with Danish Animal Research guidelines
and approved by theDanishAnimal Experiments and Inspec-
torates, with number 2011/561-1959.
2.3. Study Design. The schematic drawing in Figure 1 illus-
trates the study designs. The animals were divided into
two experimental groups. Group 1 had twelve normal rats,
and group 2 had twelve osteoporotic rats. In both groups,
the effects between ABM/P-15 and empty control on defect
healing were compared. Side location of ABM/P-15 and
empty defect in left or right proximal tibia was randomized.
After in vivo scanning, all tibias were harvested and prepared
for histologic and histomorphometric analyses (Figure 1).
Specific procedures are described below.
2.4. Surgical Procedures. Surgical procedureswere performed
at the Biomedical Laboratory, University of Southern Den-
mark.
2.4.1. Ovariectomy (OVX). Animals were anesthetized with
0.3mL/100 g of bodyweight of Hypnorm (VetaPharma Ltd.,
Leeds, UK) and Midazolam (B. Braun, Melsungen, Ger-
many) mixture subcutaneously. Initial analgesics were given,
0.2mL/100 g of bodyweight of Temgesic (RBPharmaceuticals
Limited, Berkshire,UK).Once anesthetized, the animalswere
shaved on the lumbar part of the back. A midline dorsal
skin incision was made. Blunt dissection of the connective
tissue between skin and muscle layer gave access to the
abdominal wall. The muscular layer was perforated 2 cen-
timetres lateral of the dorsal midline to gain access to the
abdominal cavity. The ovary, located surrounded by a large
fat pad, was pulled out the incision and fixated. Two ligatures
of absorbable 5.0 ethilon sutures were placed between the
uterine horn and the ovary. The ovary was safely cut off
and the uterine horn was placed back into the abdominal
cavity. The muscle layer was closed with absorbable 5.0
sutures. Bilateral ovary resection was performed from the
same initial median incision. After resection, the wound
was carefully closed in layers with 4.0 ethilon sutures. After
surgery, analgesic, Temgesic 0.2mL/100 g of bodyweight, was
administered subcutaneously three times a day for three days.
2.4.2. Tibial Surgery for Creating Defect (Called “Surgery”
Below). These animals were anesthetized by the same
method as described above. When anaesthesia was achieved,
both hind limbs were shaved. An incision, approximately
8mm in length was made on medial proximal tibia. Blunt
dissection of connective tissue gave access to the medial
surface of proximal tibia. A defect was created with a 2mm
diameter k-wire and a 2.8 diameter drill in a frontal plane
from medial side towards the lateral cortical shell. The
cylindrical defects had a diameter of 2.8mm and a depth of
3mm, thus a total volume of 18.47. Care was taken not to
drill through the lateral cortical shell.The defect was cleansed
for bone remnants and blood. The defect was either filled
with ABM/P-15 or left empty. After filling the defect, the
wound was closed in layers with 4.0 ethilon sutures. In total,
forty-eight proximal tibial cylindrical defects were created
in twenty-four rats. Analgesics, Temgesic 0.2mL/100 g of
bodyweight, were administered three times a day for 4 days
postoperatively. The animals were allowed to move without
any restrictions.
2.5. Micro-CT Scanning and Microarchitectural Analysis. All
rats were scanned in vivo with a high-resolution micro com-
puted tomographic system (vivaCT40, Scanco Medical AG,
Bru¨ttisellen, Switzerland) using 55 kVp and 72𝜇A.During the
induction of osteoporosis period, the osteoporotic rats were
in vivo micro-CT scanned at 3 time points: (1) right after
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Figure 1: Study design. Schematic flowchart drawing illustrates the study design and the preparation of the bone samples. After in vivo 𝜇CT
scanning at four time points, 42 tibias were harvested from 21 rats. The proximal ends of each tibia containing the defect site were decalcified
and embedded in paraffin for histomorphometric analyses.
ovariectomy at the same day (defined as week day −90, that is,
3 months before tibia surgery); (2) one week before the tibia
surgery (day −7); (3) day of surgery (day 0, preoperatively).
During the defect healing period, both groups were scanned
with in vivo micro-CT at four time points, immediately
following surgery at the same day serving as baseline (day
0, postoperatively), day 7, day 14, and day 21 postoperatively,
respectively.
All scans were based on the same control file, and the
same region of interest was scanned.During in vivo scanning,
the rat was anesthetized using Isoflurane (IsoFlo vet, Abbott
Laboratories Ltd., Berkshire, England). The rat was initially
placed in a chamber filled with isoflurane to reach acceptable
anaesthetic condition, and the anaesthesia was maintained
with amask during scanning process. Each scan took approx-
imately 30min and created 381 micro-CT images slices. All
scanned micro-CT images resulted in 3D reconstruction
cubic voxel sizes of 10.5 × 10.5 × 10.5 𝜇m3 (2048∗2048∗2048
pixels) with 32-bit gray levels. The images were segmented
using the segmentation techniques described in detail previ-
ously [21, 22] to obtain accurate 3D imaging datasets.
The changes of microarchitectural properties in proximal
tibial cortical bone during development of osteoporosis
were evaluated. These parameters were cortical porosity (%),
bone surface density (mm−1), bone surface to volume ratio
(mm−1), pore size (𝜇m), and cortical thickness (𝜇m).
The changes of microarchitectural parameters in prox-
imal tibial cancellous bone during development of osteo-
porosis were also quantified. These parameters were bone
volume fraction (BV/TV) [23], bone surface density (BS/TV),
bone surface-to-volume ratio (BS/BV), structuremodel index
(SMI), connectivity density (mm−3), trabecular separation
(TbSp∗), degree of anisotropy (—), and trabecular thickness
(TbTh∗).
The progress of defect healing bone mass was evaluated
similar to above description for cancellous bone.
2.6. Histomorphometry. Three weeks after surgery, rats were
euthanized using CO
2
and the tibiae were harvested and
prepared for further histology and histomorphometry.
Stereological histomorphometry was used to quantify
volume fractions of tissue inside the defect area using an
Olympus BX 51 Microscope (Ballerup, Denmark). Bone
samples were fixed in 4% formaldehyde. Specimens were
dehydrated in graded ethanol 77–96% and then paraffin
embedded for classical histomorphometry of bone formation
parameters [24]. Each bone sample was sawed into 3 sections
of 3 sectioning levels (4 𝜇m thickness with 500𝜇m separation
between each sectioning level, thus 9 sections per specimen).
All sections were stained with haematoxylin and eosin.
Stereological software (newCAST, Visiopharm, Den-
mark) was used to quantify volume fractions in predefined
regions of interest (ROI), being the defect area. Volume
fractions of bone, fibrous tissue, ABM/P-15 remnants, and
marrow cavity were estimated by using point-counting tech-
nique [25].Three sections were chosen in order to reduce the
variance of the estimates [26]. The quantified area fraction
of bone was defined as newly formed bone. Micro-CT could
not distinguish between bone and ABM/P-15 remnants in the
defect area. This was taken into account when comparing
with micro-CT data.
2.7. Statistical Analysis. All results are expressed as mean for
group ± SD. One-way ANOVA and Friedman test were used
to calculate possible differences between groups. Post hoc
multiple comparisons were adjusted using Bonferroni test
or Dunnett’s test as appropriate for normal and nonnormal
distributed data. Histomorphometric parametric data was
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Figure 2:Microarchitectural changes during the induction of osteo-
porosis. Graphic presentation of the development of osteoporosis
in ovariectomized rats. 12 rats were ovariectomized three months
prior to the surgery for creating defect. Bone loss was expressed
as mean for each parameter. Significantly deteriorated microarchi-
tecture could be observed after 11 weeks, with reduction in bone
volume fraction (BV/TV) 65.5% and connectivity density (CD)
77.5%, and more importantly these changes remained constant.
Cortical thickness (CoTh), trabecular thickness (TrTh), and degree
of anisotropy (DA).
analyzed with Student’s paired 𝑡-test or nonparametric data
withWilcoxon Rank as appropriate. 𝑃 value less than 5% was
considered significant.
3. Results
3.1. Animals. The mean weight gain of the animals in the
osteoporotic group was 48.4 grams (SD = 34.2 grams) in
contrast to the normal group, which showed a nonsignificant
mean weight gain of 28.0 grams (SD = 34.5 grams) during the
study period.
Three animals were lost from the normal group during
the 𝜇CT scanning period due to anaesthesia, leaving nine rats
for further analysis. No animals were lost in the osteoporotic
group. Three sections in normal group and two sections in
osteoporotic group were damaged during the preparation
procedure, were unusable for histological analysis, and were
excluded. Nine normal group rats and twelve osteoporotic
group rats were included in the analysis.
3.2. Microarchitectural Analysis of Osteoporotic Bone during
the Induction Period. The animals in the OVX group showed
marked decreases in bone volume fraction (65.8%, 𝑃 <
0.0001) and connectivity density (77.8%, 𝑃 < 0.0001),
indicating a marked loss of cancellous bone during the
induction period prior to surgery, that is, three months after
OVX (Figure 2). Decrease was also seen in bone surface
density (57.1%, 𝑃 < 0.0001) and trabecular thickness (9.1%,
𝑃 = 0.0006) three months after OVX. In contrast significant
increases were seen in bone surface-to-volume ratio (40.4%,
𝑃 = 0.0001), structure model index (252.2%, 𝑃 < 0.0001),
and trabecular separation (118.9%, 𝑃 = 0.0017) three months
after OVX. Degree of anisotropy showed only significant
increase between day −90 and day −7 before surgery (5.9%,
𝑃 = 0.0265) (Table 1).
For cortical bone, cortical porosity was not changed
(18.2% reduction, 𝑃 = 0.1794) three months after OVX
(Figure 2 and Table 2). Seven days before surgery, significant
decreases were seen in bone surface density (24.3%, 𝑃 =
0.0001) and bone surface-to-volume ratio (22.2%, 𝑃 =
0.0001). Significant increase was also seen for pore size
(66.7%, 𝑃 = 0.0018) after three months. Cortical thickness
showed a small increase after threemonths (1.8%,𝑃 = 0.0003)
(Table 2).
3.3. Microarchitectural Analysis of Calcified Material in
Cylindrical Defect Region
3.3.1. Changes in Microarchitecture in Normal Rats. Seven
days after surgery, degree of anisotropy decreased for the
empty group (𝑃 = 0.002), but the ABM/P-15 group showed
increase from day seven to day fourteen (𝑃 = 0.037).
Fourteen days after surgery, bone surface density (𝑃 <
0.001) and connectivity density (𝑃 < 0.001) increased
for both the empty group and the ABM/P-15 group. Only
ABM/P-15 group decreased in trabecular thickness (𝑃 <
0.001) (Figure 3).
Twenty-one days after surgery, bone volume fraction
increased for both the empty group (𝑃 < 0.001) and the
ABM/P-15 group (𝑃 < 0.001) (Figure 3). Structure model
index decreased for the empty group (𝑃 < 0.001) and for
the ABM/P-15 group (𝑃 < 0.001). Trabecular separation
decreased for the empty group (𝑃 < 0.001) and for the
ABM/P-15 group (𝑃 < 0.001).
Bone surface-to-volume ratio decreased for the empty
group (𝑃 < 0.001) after twenty-one days but increased after
fourteen days from 28.3mm−1 to 39.6mm−1 for the ABM/P-
15 group (𝑃 < 0.001) (Table 3).
3.3.2. Changes in Microarchitecture in Osteoporotic Rats.
Seven days after surgery, trabecular thickness decreased for
the empty group (𝑃 < 0.001) (Figure 3). Degree of anisotropy
decreased only for the empty group (𝑃 = 0.001).
Fourteen days after surgery bone surface density (𝑃 <
0.001) and connectivity density (𝑃 < 0.001) increased for
both the empty group and the ABM/P-15 group. Bone volume
fraction increased for the empty group (𝑃 < 0.001) (Figure 3).
Structure model index decreased after fourteen days,
for the empty group (𝑃 < 0.001). Trabecular separation
decreased both for the empty group (𝑃 < 0.001) and for
the ABM/P-15 group (𝑃 < 0.001). A decrease in trabecular
thickness for the ABM/P-15 group (𝑃 < 0.001) was seen after
fourteen days (Figure 3).
Twenty-one days after surgery, bone surface-to-volume
ratio was decreased only for the empty group (𝑃 < 0.001).
An increase in bone volume fraction for the ABM/P-15 group
was seen after twenty-one days (𝑃 < 0.001). Structure model
index decreased after twenty-one days, for the ABM/P-15
group (𝑃 < 0.001) (Table 4).
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Figure 3: Microarchitectural changes after surgery for creating defect in the normal and the osteoporotic rats. Microarchitectural parameters
of the tibial defect areas in normal and osteoporotic rats are presented. Square points represent values from empty groups. Round points
represent ABM/P-15 groups. Values are expressed as mean ± SD for groups and are depicted in normal group (a, c, e, g) and in osteoporotic
group (b, d, f, h).
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Table 1: 3D microarchitectural properties (mean ± SD) of cortical bone in osteoporosis induction period.
Cortical
porosity (%)
Bone surface
density (mm−1)
Bone surface-to-volume
ratio (mm−1) Pore size (𝜇m)
Cortical thickness
(𝜇m)
D −90 (𝑁 = 12) 2.4 ± 1 5.48 ± 0.53 5.62 ± 0.54 0.03 ± 0.004 0.28 ± 0.02
D −7 (𝑁 = 12) 2.9 ± 1 4.15 ± 0.51 4.37 ± 0.52 0.04 ± 0.008 0.32 ± 0.02
D0 (𝑁 = 12) 2.8 ± 1 5.41 ± 0.7 5.69 ± 0.72 0.05 ± 0.02 0.28 ± 0.03
ANOVA P = 0.1794 P < 0.001 P < 0.001 P = 0.002 P < 0.001
Difference between groups NS D −7 < D −90, D0 D −7 < D −90, D0 D −90 <D −7 <D0 D −7 > D −90, D0
D0 = day 0, D−7 = day−7, andD−90 = day−90 before bone surgery. Values are expressed asmean for group, measured on both hind legs ± standard deviation.
NS = no significance. 𝑃 values < 0.05 are considered significant.
3.4. Histology. Defects in the ABM/P-15 group showed obvi-
ous remodelling and new bone formation in direct apposition
to ABM/P-15 in both normal and osteoporotic rats. Most
of the remnant ABM/P-15 particles in the defects were
completely surrounded by newly formed bone. The contact
surfaces between newly formed bone andABM/P-15 particles
were in general solid and continuous (Figure 4). The defects
that were left empty showed considerable more bone growth
in normal bone than in osteoporotic bone.
3.5. Histomorphometry. Therewas no difference in new bone,
fibrous tissue, residual unabsorbed ABM/P-15 or marrow
cavity, between the empty group and the ABM/P-15 group,
in normal rats (Figure 5).
In osteoporotic rats, the empty group had 17.7% of new
bone in the defect area, which was significantly less than
39.9% new bone in the ABM/P-15 group (paired 𝑡-test 𝑃 <
0.0001). The empty group showed 43.8% fibrous tissue and
38.4% marrow cavity in the defect area, which both were
significantly more than 31.6% fibrous tissue (paired 𝑡-test 𝑃 =
0.0005) and 13.9% marrow cavity (paired 𝑡-test 𝑃 < 0.0001)
in the ABM/P-15 group. 14.6% residual unabsorbed ABM/P-
15 was seen in the ABM/P-15 group.
4. Discussion
In this study, the effects of ABM/P-15 on bone defect healing
were investigated in tibia defect models in both normal and
osteoporotic rats [27]. The changes in microarchitectural
parameters were significant for all groups during the observa-
tion period of twenty-one days. Histomorphometry revealed
significantly improved defect repair in the osteoporotic
ABM/P-15 group compared with the empty group. These
results indicate that ABM/P-15 significantly promoted new
bone formation in osteoporotic bone but did not accelerate
new bone formation in normal bone. These results did
support our hypothesis that bone repair in osteoporotic
bone was significantly accelerated by ABM/P-15, but not
that ABM/P-15 would enhance bone repair in normal bone.
Furthermore, histology demonstrated extensive new bone
formation adjacent to ABM/P-15 with direct contact between
bone and ABM/P-15. These findings suggest that ABM/P-15
grafting material provides osteoconductive and osteoinduc-
tive properties, both being important characteristics of an
ideal bone graft substitute [28–30].
A few studies have tested the effects of ABM/P-15 on
different types of bone defects in small and large animal
models, but no longitudinal studies have been done.
We have recently demonstrated the efficacies of ABM/P-
15 on bone formation and implant fixation in sheep, and these
effects were at least as good as allograft [31]. Scarano et al.
[32] showed that ABM/P-15 enhanced new bone regeneration
in 8mm tibial cortical defects in rabbits. The newly formed
bone surrounding the residual P-15 particles after 4 weeks
was more mature compared with bone formed in untreated
empty defects. Wojtowicz et al. [33] found accelerated and
increased bone formation in 8mm segmental femur defect in
rats treatedwithGFOGER, a triple helical peptide that similar
to ABM/P-15 binds to the 𝛼2𝛽1-integrin receptor. A clinical
pilot study by Gomar et al. [18] showed full consolidation
healing in delayed and nonunion extremities fractures in
twenty of twenty-two human cases. Full consolidation was
determined radiographically as callus formation in the full
thickness of the bone.
Some studies have reported that ABM/P-15 did not
promote new bone formation. Sarahrudi et al. [34] showed
reduced production of new bone in defects treated with
ABM/P-15 compared with empty control defects after 8 to
12 weeks, in a 5mm segmental rabbit femur defect. Mardas
et al. [35] demonstrated that ABM/P-15 failed to promote
bone healing in critical sized rat calvarial defects, compared
with untreated controls. There was no significant difference
between treatment group and control group 60 days or 120
days postoperatively.
In the present study the effect of ABM/P-15 on osteo-
porotic bone defects was evaluated. We observed a decrease
in cancellous bone volume fraction of 66.2%, a decrease in
trabecular thickness of 9.1%, and a decrease in connectivity
density of 77.8% after three months. Cheng et al. [36] showed
a 19.5% decrease in bone mineral density of the lumbar spine
in a rat after three months. Heiss et al. [37] showed a 15.7%
decrease in bone mineral density also after three months.
Campbell et al. [38] showed a 37% decrease in cancellous
bone volume fraction, in rat proximal tibiae after eight weeks.
Furthermore, they showed significant decrease in trabecular
thickness and connectivity density. Boyd et al. [39] have
observed similar development after three months. In this
study cortical thickness showed a 1.8% increase after three
months. Similar changes in cortical bone have been reported
in earlier studies [38]. The changes in cancellous bone in
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Figure 4: Histological images of defect repairs for both normal and osteoporotic rats. Histology images of defects in normal bone (a, c, e)
and osteoporotic bone (b, d, f) are shown. Black arrows indicate residual ABM/P-15 particles inside the defect areas. Size lines in bottom right
corner represent 1mm (a–d) and 250 𝜇m (e and f).
ovariectomized rats were similar to reported ongoing changes
in human normal aging bone and osteoporotic bone [40].
Thus this model was highly clinically relevant.
Histological and histomorphometric analyses did not
show improved bone defect healing in normal rats, when
comparing the ABM/P-15 group with the empty group after
twenty-one days.This supports the finding of an earlier study
[34]. One explanation would be that the defect area was too
small (2.8mm in diameters) to expect impaired bone regen-
eration in normal bone. Interestingly, bone volume fraction
of the ABM/P-15 group in osteoporotic rats reached the same
level as the ABM/P-15 group in normal rats indicating that
ABM/P-15may optimize the healing potential in osteoporotic
bone. Histomorphometry results showed similar fractions
of bone in the defect areas of the ABM/P-15 treated groups
in both normal and osteoporotic rats. In osteoporotic rats,
the bone repair potential was impaired. It was thus of great
interest to see a significant improvement of bone formation
in the ABM/P-15 group compared with the empty group (𝑃 <
0.001) in osteoporotic bone. Slight decreases in bone volume
fractions were observed in both ABM/P-15 groups after seven
days. An initial inflammatory process, as described byTsiridis
et al. [41] before bone regeneration begins, might explain this.
Bone surface density in osteoporotic rats and connectivity
density in all rats showed highest increase after fourteen
days. From day fourteen to day twenty-one both parameters
decreased. For the ABM/P-15 groups, this development could
indicate that new bone initially was formed on the surface of
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Figure 5: Results from histomorphometrical analysis of defect repairs for both normal and osteoporotic rats. Results of histomorphometric
analysis for normal and osteoporotic rats 21 days after surgery are presented. Each dot represents mean value of three measurements 500𝜇m
apart in one defect. Horizontal lines express mean for group.
the ABM/P-15 grafting material, then the increase, followed
by a new bone formation inside the ABM/P-15 material,
and then the decrease. These events could also explain the
development in bone surface-to-volume ratio, where an ini-
tial increase was observed, followed by a decrease after
twenty-one days in both the ABM/P-15 groups in both
normal and osteoporotic rats.
Trabecular thickness in the ABM/P-15 groups, both nor-
mal and osteoporotic rats decreased significantly from day
zero to day fourteen. As a consequence of increased bone
12 BioMed Research International
tissues, structure types were changed toward a typical plate-
like structure, while the structure types in the empty groups
remained a typical rod-like structure.
Histologically, substantial bone growth was observed
around ABM, indicating that it accelerated bone formation.
This might be explained by increased and strengthened cell
adhesion due to actin filaments and stress fibres. Further-
more, cells adhered toABM/P-15 have been shown to increase
osteoblastic gene expression for BMP-2, BMP-7, and alkaline
phosphatase and to increase matrix deposition [20]. Palmieri
et al. [42] demonstrated an upregulation of 11 miRNA genes,
involved in osteogenesis and bone remodelling, in human
osteoblast-like cells cultured with P-15 peptide. Histological
findings in this study indicated that ABM/P-15 had osteoin-
ductive properties [42]. In our study, ABM/P-15 defects had
an initial bone volume fraction of 30.2% at day 0, because
of the inserted graft material. It was expected that ABM/P-15
would be resorbed over time. By day twenty-one, 9.5% of total
defect area volumewasABM/P-15material in normal rats and
14.6% in osteoporotic rats. Sherman et al. [10] showed 9±7.3%
residual of ABM/P-15 in the observation site six months after
surgery in an ovine lumbar interbody fusion model. This
suggested that the reabsorbing process of ABM/P-15 started
within the first weeks of bone healing. Assuming that a part
of the graft material has been reabsorbed and replaced by
newly formed bone, there could be a tendency to improved
bone regeneration in ABM/P-15 treated defect in normal
bone.
Taken together, ABM/P-15 accelerated bone regeneration
in osteoporotic bone to the same extent as in normal
bone on several parameters such as bone volume fraction,
surface density, connectivity density, and trabecular thickness
suggesting that ABM/P-15 did accelerate bone healing in
osteoporotic bone, but not in normal bone.
Despite the above-mentioned literatures, the efficacy of
ABM/P-15 on defect repair in vivo longitudinally has not
been investigated, more importantly not in an osteoporotic
model. Thus, the present study tried to elucidate the effects
of ABM/P-15 on bone defect healing in both normal and
osteoporotic rat tibias. This design was highly clinically
relevant and particularly important for osteoporotic patients.
Thus, this studywas able to answer to efficacy ofABM/P-15 on
bone defect repair and whether results derived from normal
bone could be similar to those from osteoporotic bone.
There are several limitations of the study. A group treated
with ABM alone (without P-15 coating) could have been
used to serve as a control group, which could have helped
clarifying the specific effect of the P-15 coating. Additionally,
a group treated with autograft would have provided insight
to whether ABM/P-15 could be an alternative to autograft as
gold standard grafting material for orthopaedic surgery.
Day zero bone volume fraction values in the two empty
groups were not identical. This could be a bias in comparing
the empty groups. Although the same techniques were used,
the bone volume fractions in the two empty groups on day
zero were not identical. This small (1.5% versus 2.6%) but
significant difference was due to uncleaned bone fragments
left inside the holes and could cause a bias in comparing the
empty groups.
ABM/P-15 and newly formed bone could not be differ-
entiated with micro-CT scanning, because of overlapping of
image grey values with similar density profiles. This could
have been a weakness in evaluating new bone formation by
micro-CT. We solved this problem by using histology and
histomorphometry to evaluate new bone formation at sacri-
fice. Due to remnants of ABM/P-15 in the defect site, it was
not possible to blind the histological analysis of the bone
specimens.
The empty groups showed a relative good healing poten-
tial in this rat model. Therefore the tibial defects in this study
were not critically sized.
In conclusion, this study showed that ABM/P-15 signif-
icantly enhanced bone defect repair in a 2.8mm cylindrical
proximal tibia defect in osteoporotic rats, while ABM/P-15
did not accelerate bone defect repair in normal rats.
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